Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREAM: durvalumab + etoposide + carboplatin for ES-SCLC with mild idiopathic interstitial pneumonia
jRCTs051200109Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of durvalumab, etoposide and carboplatin in small cell lung cancer (SCLC) and idiopathic interstitial pneumonia (IIP), sponsored by AstraZeneca. Primary endpoint: Severe_pneumonitis-free rate. Started Jan 2021; status: completed.
02
Drugs
durvalumabetoposidecarboplatin
03
Conditions
small cell lung cancer (SCLC)idiopathic interstitial pneumonia (IIP)
Beyond the preview
Go deeper on jRCTs051200109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051200109.